New hope for 10x’ preliminary injunction after EPO Opposition Division ruling | Patent at issue concerns single-cell spatial ...

Buy 10x Genomics with a 1-year target of $12.7, projecting 18% growth. Read here for more on TXG stock's biopharma potential ...

The firm is using single-cell, multiomics analysis to probe tumor samples from very long-term cancer survivors for keys to defeat the disease.

BACKGROUND: Despite the high morbidity and mortality of heart failure with preserved ejection fraction (HFpEF), treatment ...

What a brutal six months it’s been for 10x Genomics. The stock has dropped 52.1% and now trades at $10.59, rattling many ...

Cure51 and Assistance Publique – Hôpitaux de Paris have partnered to identify biomarkers for long-term survival in pancreatic cancer.

Parse’s latest innovations include the recent launch of their Evercode Penta kit, the largest ever single cell sequencing kit that allows researchers to look at up to 5 Million cells in a single ...

Finally, Citigroup reduced their price target on shares of 10x Genomics from $23.00 to $20.00 and set a “buy” rating on the stock in a research report on Thursday, February 13th. One analyst ...

Bill Lee’s desk. Tennessee is one of several states considering similar statewide policies this year. “With everything that we have learned about the harm that cell phones are doing ...